Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert K. who wrote (10792)	7/17/1999 2:33:00 AM
From: John Romeo	Read Replies (1) \| Respond to of 17367

Robert, in discussing the 'downregulation in the inflammitory chain', are you seeing bpi as secondary indication on complement inhibition, the well discussed cascade. If so, then we go to many new applications ,ARDS,Repurfusion injury,implant rejection, sepsis etc. and the list goes on. I am no scientist. I do know a little about complement system,almost lost father to ARDS. Where is the data on bpi meeting these therapuetic indications, off label, or are there ongoing trials of bpi in these indications. Thanks for your well thought insight.